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ABSTRACT
Although quinolones are theoretically interesting candidates for the treatment of brucellosis, the existing
data concerning their efficacy are limited and conflicting. A number of small clinical studies with
combination regimens that include quinolones have shown adequacy, but not superiority, although
cost-effectiveness, excluding certain disease complications, is an important issue. The emergence of
quinolone resistance and its implications is another drawback. Experimental data have yielded
contradictory results, although most studies do not indicate a bactericidal effect for quinolones.
However, in-vitro studies contrast repeatedly with the clinical response, both in terms of clinical failure,
despite in-vitro success, and vice versa.
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Treatment of brucellosis, which is prevalent
worldwide and may be re-emerging as a zoonosis
[1], has not changed significantly in the past half-
century, and still utilises various combinations of
‘traditional’ antibiotics, such as tetracyclines,
streptomycin and rifampicin [2]. Although the
regimens advocated currently for use during the
suggested period of administration do not exhibit
total efficacy, advances in the field of brucellosis
treatment have been restricted largely to the
addition of a third drug (usually trimethoprim-
sulphamethoxazole), and the demonstration that
other aminoglycosides can substitute successfully
for streptomycin [3]. The increased use of quino-
lones during the last 20 years has attracted inter-
est towards their theraputic potential for
brucellosis, largely because of the acknowledged
antimicrobial action of quinolones in the intra-cel-
lular environment that is exploited by Brucella.
However, the role of quinolones in the treatment
of brucellosis is far from defined, despite a
number of laboratory, experimental and clinical
studies. Two factors that may explain the absence
of a defined role are the small number and range
of clinical studies, and the discrepancy between
in-vitro observations and in-vivo efficacy,
although these factors are just part of the overall
puzzle of treatment for brucellosis.
A limited number of clinical trials using quino-
lones for the treatment of brucellosis have been
published in the medical literature [4–15] (i.e.,
studies that are not isolated case reports, that do
not involve serious complications of brucellosis,
such as endocarditis and neurobrucellosis, and
that include adequate data concerning diagnosis
and follow-up). Pooled data from these studies
are shown in Table 1. The various regimens
employed, the small cumulative number of
patients treated, and the significant variance
between the reported efficacies within some
sub-classes of patients, preclude any attempt at
a meta-analysis of these results. In total, 32
(19.2%) of 167 patients treated with any quino-
lone-containing regimen relapsed or failed to
respond, although this percentage drops to 15%
if attempts to use monotherapy are excluded. The
small overall number of patients, and the fact that
not all of these trials were comparative, precludes
statistical evaluation of the response in compar-
ison with traditional regimens. Data concerning
toxicity, which was variably present, show a
similar adverse reaction and side-effect profile to
that of traditional regimens.
Practically every agent belonging to the quino-
lone family has been tested in vitro for its efficacy
against brucellosis [16]. The aim of in-vitro stud-
ies is to evaluate the efficacy of quinolones in the
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acidic environment of the phagolysosomal com-
partment of macrophages, which serve to protect
Brucella inside the human body. Laboratory stud-
ies have shown that traditional markers of bac-
teriostatic effect (e.g., the MIC) depend on the
environmental pH and the initial bacterial load
[17], perhaps explaining, at least for the latter,
why each case of brucellosis may respond in a
different manner to antibiotics. Furthermore,
studies have also demonstrated an absence of
bactericidal activity with most quinolones [17,18].
Further support comes from animal models, since
quinolones failed universally to obtain a favour-
able response even in combination regimens [19].
However, experimental results obtained in
murine models may not reflect human disease
accurately, since the differences in virulence and
host response may influence the quinolone effect.
Do in-vitro observations transform to clinical
practice? Studies that have shown the absence of
an adequate bactericidal effect for ciprofloxacin
also indicate that such a bactericidal effect can
only be achieved optimally with aminoglycosides
[18], despite the fact that aminoglycosides do not
penetrate efficiently into macrophages! The vari-
ability of rifampicin bacteriostatic parameters
among different studies (often reaching unaccept-
able values) is another typical example, since
rifampicin is an acknowledged component of the
currently accepted optimal regimens. Experimen-
tal observations may not adequately simulate the
real environment in which the antibiotic–Brucella
interface takes place.
The inadequacy of laboratory models is also
illustrated by a comparison of clinical data
(Table 1) with in-vitro results. Although the land-
mark study of Rubinstein et al. [20] demonstrated
possible antagonism between ciprofloxacin and
doxycycline by using killing curves, ten cases in
which a combination of the two antibiotics were
used (five if patients with a protracted treatment
period are excluded) showed an excellent re-
sponse (Table 1), with no relapses recorded. On
the other hand, a recent case report [21] described
how use of the optimal in-vitro combination of
ciprofloxacin and doxycycline failed to cure the
patient. Comparative trials with ofloxacin and
rifampicin, a combination that has demonstrated
antagonism in experimental settings [22], have
shown an efficacy comparable to that of the
traditional doxycycline-rifampicin regimen.
The contradictory results of these studies, and
the absence of any demonstration of clinical
superiority, imply that there is no therapeutic
role for quinolones in brucellosis, since non-infe-
riority is insufficient if cost-effectiveness is taken
into account. However, clinical trials indicate that
certain clinical situations may justify further
experimentation with quinolones. A typical exam-
ple is the possible role of quinolones in treating
spondylitis [4], taking advantage of the affinity of
quinolones for bone and soft-tissues.
An important parameter that could preclude
the use of quinolones for treating brucellosis may
be the risk for resistance development. Serial
studies have documented that use of ciprofloxacin
can be followed by the development of resistance,
with cross-resistance emerging to most other
members of the family [23]. Quinolone resistance
in Brucella is related, at least partly, to the
expression of NorM1. This protein mediates
multidrug resistance [24], which could possibly
extend to aminoglycosides. However, similar
worries concerning the emergence of resistance
Table 1. Pooled data from clinical studies utilising quinolones for the treatment of brucellosis
Regimen used Existing data and reference Pooled data
Ciprofloxacin only, dosage varying 14 patients, 3 failures [10] 36 patients, 12 failures (33%)
6 patients, 5 failures [12]
16 patients, 4 failures [11]
Ciprofloxacin and doxycycline, usual doses 2 patients, no failures [7] 5 patients, no failures (0%)
(excluding *, treated for 3 months)
3 patients, no failures [10]
5 patients, no failures [4]*
Ofloxacin and rifampicin, usual doses 27 patients, 2 failures [8] 92 patients, 15 failures (16%)
15 patients, 2 failures [5]
19 patients, 10 failures [6]
31 patients, 1 failure [15]
Ciprofloxacin and rifampicin, usual doses 5 patients, 1 failure [10] 25 patients, 4 failures (16%)
20 patients, 3 failures [9]
(30-day regimen, same as control arm)
Ciprofloxacin and streptomycin, usual doses 3 patients, 1 failure [10] 3 patients, 1 failure (33%)
Pefloxacin in various combinations, usual doses 5 patients, no failures [10] 5 patients, no failures (0%)
Ofloxacin monotherapy Not available Failure 16% [13] [14],
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to rifampicin have not halted its extended use for
the treatment of brucellosis.
Is there a place for quinolones in the treatment
of human brucellosis? Progress in understanding
the molecular pathogenesis of the disease may
help to clarify the precise interactions between
host, microbe and antibiotics, thereby allowing a
more specific in-vitro simulation of the intra-cel-
lular environment, and the development of more
accurate predictors of antibiotic response. Larger,
adequately planned, clinical trials could then
investigate the overall efficacy and cost-effective-
ness of quinolone-containing therapeutic regi-
mens for the treatment of this disease.
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